Alexion Pharmaceuticals - Company & Market Research Reports

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Alexion developed Soliris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris is approved in more than 50 countries for PNH and more than 40 countries for aHUS. Alexion's company headquarters are based Cheshire, Connecticut, United States.

From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator
adroll